Skip to main content

Cormorant Asset Management — Portfolio, Page 6

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

205
Companies
$24.7B
Total invested
$149.5M
Avg. check
15
Industries
Biotechnology 19Health Care 16Medical 13Therapeutics 12Life Science 7Pharmaceutical 4+9 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 121144 of 205
Tango Therapeutics
October 2025

Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.

Biotechnology · Cambridge$197.0M Post Ipo Equity
Electra Therapeutics
October 2025

Electra Therapeutics is a clinical-stage biotechnology company developing antibody therapies for immunological diseases and cancer.

Biotechnology · San Francisco$183.0M Series C
Spyre Therapeutics
October 2025

Spyre Therapeutics is a biotechnology business that is developing a strong pipeline of antibody therapies.

Biotechnology · Sunrise$275.0M Post Ipo Equity
Biomea Fusion
October 2025

Biomea Fusion is a precision oncology company developing novel small molecules that target aggressive forms of cancer.

Biotechnology · Redwood City$25.0M Post Ipo Equity
Star Therapeutics
October 2025

Star Therapeutics mission is to develop therapies for as many diseases as possible for millions of patients.

Health Care · South San Francisco$125.0M Undisclosed
Averto Medical
October 2025

Averto Medical is a medical device manufacturing company.

Health Care · Belmont$2.1M Grant
Ensoma
September 2025

Ensomaa is a genomic medicine company that develops on one-time in vivo treatments for immuno-oncology and other therapeutic applications.

Biotechnology · Boston$53.0M Series Unknown
Oruka Therapeutics
September 2025

Oruka Therapeutics is advancing innovative biologics to redefine patient care standards in chronic skin diseases.

Biotechnology · Waltham$180.0M Post Ipo Equity
Tioga Cardiovascular
September 2025

Tioga Cardiovascular is a healthcare company providing valve replacement solutions for mitral and tricuspid applications.

Health Care · Campbell$22.9M Series D
Avidity Biosciences
September 2025

Synapse Energy Economics is a consulting firm providing economic and policy analysis for the electric power sector.

Biotechnology · San Diego$690.0M Post Ipo Equity
Rapport Therapeutics
September 2025

Rapport Therapeutics is a clinical-stage biotechnology company that discovers and develops precision medicines for neurological disorders.

Biotechnology · Boston$250.0M Post Ipo Equity
Ruizheng Gene
August 2025

AccurEdit develops safe, targeted in vivo gene editing and delivery tech for severe hereditary and acquired diseases.

Biotechnology · Suzhou$75.0M Series A
BBOT
August 2025

BBOT is a clinical-stage biopharmaceutical company advancing a pipeline of novel therapeutics targeting RAS and PI3Kα malignancies.

Biopharma · Palo Alto$261.0M Post Ipo Equity
Prime Medicine
August 2025

Prime Medicine is a biotechnology company that utilizes Prime Editing to modify genetic sequences to treat a wide range of diseases.

Biotechnology · Cambridge$5.0M Post Ipo Equity
Antares Therapeutics
May 2025

Antares is a biotechnology company focused on developing transformational,medicines targeting validated cancer and other serious diseases.

Biopharma · Boston$177.0M Series A
Fore Biotherapeutics
May 2025

Fore Biotherapeutics is a precision oncology company specializing in cancer therapies guided by functional genomics.

Biotechnology · Philadelphia$40.2M Series D
Attovia Therapeutics
April 2025

Attovia Therapeutics is a biologics platform specializing in biotherapeutics for immune-mediated diseases.

Biotechnology · San Carlos$90.0M Series C
Edgewise Therapeutics
April 2025

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.

Biopharma · Boulder$200.0M Post Ipo Equity
Supira Medical
March 2025

Supira Medical is a clinical-stage company that develops catheter-based circulatory support devices for patients with heart conditions.

Health Care · Los Gatos$120.0M Series E
Latigo Biotherapeutics
March 2025

Latigo Biotherapeutics is a clinical-stage biotechnology company that develops novel, non-opioid therapies for chronic pain.

Biotechnology · Thousand Oaks$150.0M Series B
Stratus Therapeutics
March 2025

Stratus Therapeutics develops off-the-shelf hematopoietic stem cell therapies to treat severe and life-threatening diseases.

Biotechnology · Cambridge$50.0M Series A
Aligos Therapeutics
February 2025

Aligos Therapeutics is discovering and developing new classes of molecules that interact directly with disease-causing modalities.

Biotechnology · San Francisco$105.0M Post Ipo Equity
GH Research
February 2025

GH Research is a biopharmaceutical company developing novel therapies for the management of mental illness.

Biopharma · Dublin$150.0M Post Ipo Equity
ADARx Pharmaceuticals
February 2025

ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts.

Biotechnology · San DiegoSeries Unknown

Where Cormorant Asset Management invests

Biotechnology19
Health Care16
Medical13
Therapeutics12
Life Science7
Pharmaceutical4

About Cormorant Asset Management's portfolio

How many companies has Cormorant Asset Management invested in?

Cormorant Asset Management has invested in 205 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Cormorant Asset Management invest in?

Cormorant Asset Management's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Life Science. The firm invests across 15 different industry categories.

What is Cormorant Asset Management's largest investment?

Among tracked funding rounds, Avidity Biosciences received $690.0M in a Post Ipo Equity round. Cormorant Asset Management's total known invested capital is $24.7B.

What is the average investment size for Cormorant Asset Management?

Cormorant Asset Management's average investment size is $149.5M across its portfolio of 205 companies.

What are Cormorant Asset Management's most recent investments?

Recent Cormorant Asset Management portfolio additions include Tango Therapeutics, Electra Therapeutics, Spyre Therapeutics, Biomea Fusion, Star Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 205 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →